BAX — Baxter International Inc.

Baxter International Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Global Sales: $2.7 billion, up 3% year-over-year (YoY) on a reported basis but down 1% on an organic basis.
• Adjusted Earnings: $0.36 per diluted share, a decrease of 35% from $0.55 in Q1 2025.
• Adjusted Gross Margin: 36.8%, down 500 basis points due to higher costs and unfavorable comparisons.
• Free Cash Flow: $76 million, a significant improvement from negative $221 million in Q1 2025.
• Adjusted Operating Margin: 11%, down 390 basis points YoY.

2. Strategic Updates and Business Highlights:

• Leadership Transition: Anita Zielinski is serving as Interim CFO while a permanent successor is being sought.
• Turnaround Strategy: Focus on stabilizing the business, strengthening the balance sheet, and driving continuous improvement through the Baxter Growth and Performance System (GPS).
• Product Innovations: Successful launches include the Dynamo smart stretcher and the IV Verified Line labeling system, with ongoing development of AI-integrated solutions.
• Segment Performance:
  • Medical Products & Therapy (MPT): Sales of $1.3 billion, down 2% YoY, impacted by Novum LVP shipment holds.
  • Healthcare Systems & Technology (HST): Sales of $705 million, down 2%, with mixed performance across divisions.
  • Pharmaceuticals: Sales of $621 million, up 1%, but faced challenges in Injectables and Anesthesia due to supply constraints.

3. Forward Guidance and Outlook:

• 2026 Sales Growth: Expected to be flat to 1% on a reported basis, with organic growth anticipated to be flat.
• Segment Expectations:
  • MPT: Flat to slightly up organic sales, contingent on resolving Novum shipment issues.
  • HST: Low single-digit growth expected, particularly in the second half.
  • Pharmaceuticals: Flat organic sales anticipated, with continued pressure from Injectables and Anesthesia.
• Adjusted Earnings Guidance: Expected to be between $1.85 to $2.05 per diluted share for the full year.

4. Bad News, Challenges, or Points of Concern:

• Operational Headwinds: Higher manufacturing costs, tariffs, and the ongoing hold on Novum LVP shipments are significant challenges.
• Market Comparisons: Q1 faced tough YoY comparisons due to a one-time distributor build in Q1 2025.
• Supply Chain Issues: Continued supply constraints in the Injectables segment and potential risks from Novum customer returns could impact future performance.
• Inflationary Pressures: Rising costs from oil and other materials remain a concern, although management believes they can mitigate these impacts.

5. Notable Q&A Insights:

• Customer Engagement: Management emphasized strong customer interest in new products and ongoing efforts to stabilize the Novum situation.
• Future Growth Drivers: Innovation is seen as a key growth driver, with specific focus on enhancing existing product lines rather than launching entirely new products.
• CFO Search: The search for a permanent CFO is underway, with a focus on finding someone who understands execution and the business.
• Confidence in Back Half of 2026: Management expressed optimism for improved performance in the second half of the year, driven by seasonal trends and the expected resolution of current challenges.

Overall, while Baxter International's Q1 2026 results reflected some operational challenges and a cautious outlook, the company is actively pursuing strategic initiatives aimed at stabilizing and improving its performance.